TY - JOUR
T1 - Delineating antibody recognition against Zika virus during natural infection
AU - Yu, Lei
AU - Wang, Ruoke
AU - Gao, Fei
AU - Li, Min
AU - Liu, Jianying
AU - Wang, Jian
AU - Hong, Wenxin
AU - Zhao, Lingzhai
AU - Wen, Yingfen
AU - Yin, Chibiao
AU - Wang, Hua
AU - Zhang, Qi
AU - Li, Yangyang
AU - Zhou, Panpan
AU - Zhang, Rudian
AU - Liu, Yang
AU - Tang, Xiaoping
AU - Guan, Yongjun
AU - Qin, Cheng Feng
AU - Chen, Ling
AU - Shi, Xuanling
AU - Jin, Xia
AU - Cheng, Gong
AU - Zhang, Fuchun
AU - Zhang, Linqi
N1 - Publisher Copyright:
© 2017 American Society for Clinical Investigation. All rights reserved.
PY - 2017/6/15
Y1 - 2017/6/15
N2 - Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that shares a considerable degree of homology with dengue virus (DENV). Here, we examined longitudinal antibody response against ZIKV during natural infection in 2 convalescent individuals. By decomposing the antibody recognition into DI/DII and DIII of the E glycoprotein, we showed their development in humans followed a spatiotemporal hierarchy. Plasma binding to DI/DII appeared to peak and wane during early infection with extensive cross-reactivity with DI/DII of DENV. Binding to DIII, however, peaked early but persisted months into the infection without detectable cross-reactivity with DIII of DENV. A clear trend of increase in DIII-specific neutralizing activity was observed over the course of infection. mAbs isolated during early infection are largely DI/DII specific, weakly neutralizing, and highly cross-reactive with DENV, while those from later infection are more diverse in recognition, potently neutralizing, and ZIKV specific. The most potent neutralizing mAb targeting the DIII provided 100% protection in mice from lethal ZIKV infection and could therefore serve as a promising candidate for antibody-based therapy and prevention. The dynamic features unveiled here will assist us to better understand the pathogenesis of ZIKV infection and inform rational design of vaccines.
AB - Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that shares a considerable degree of homology with dengue virus (DENV). Here, we examined longitudinal antibody response against ZIKV during natural infection in 2 convalescent individuals. By decomposing the antibody recognition into DI/DII and DIII of the E glycoprotein, we showed their development in humans followed a spatiotemporal hierarchy. Plasma binding to DI/DII appeared to peak and wane during early infection with extensive cross-reactivity with DI/DII of DENV. Binding to DIII, however, peaked early but persisted months into the infection without detectable cross-reactivity with DIII of DENV. A clear trend of increase in DIII-specific neutralizing activity was observed over the course of infection. mAbs isolated during early infection are largely DI/DII specific, weakly neutralizing, and highly cross-reactive with DENV, while those from later infection are more diverse in recognition, potently neutralizing, and ZIKV specific. The most potent neutralizing mAb targeting the DIII provided 100% protection in mice from lethal ZIKV infection and could therefore serve as a promising candidate for antibody-based therapy and prevention. The dynamic features unveiled here will assist us to better understand the pathogenesis of ZIKV infection and inform rational design of vaccines.
UR - http://www.scopus.com/inward/record.url?scp=85040226711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040226711&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.93042
DO - 10.1172/jci.insight.93042
M3 - Article
C2 - 28614803
AN - SCOPUS:85040226711
SN - 0021-9738
VL - 2
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 12
M1 - e93042
ER -